Aurobindo Pharma Ltd’s consolidated net profit increased 2.8 per cent at ₹₹595 crore in the the third quarter ended December 31, 2017 against ₹578.6 crore in the corresponding quarter of the previous financial year. Revenue increased by 11 per cent at ₹4,336 crore (₹3,906 crore). During the quarter, the US Formulations sale had gone up by 9.4 per cent, while the same from Europe increased 37 per cent.
The board had approved second interim dividend at 100 pc, that is, ₹1 per equity share of ₹1 for the year FY17-18.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.